Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center

Endocrine Oncology · Published 2026-08-03 · DOI 10.1530/eo-26-0038

Free full text

Authors (11)

Joao Pedro Thimotheo Batista, Michael De La Iglesia, Hyun Kim, Vikas Prasad, Ravindra Shubha, Rama Suresh, Shuang Wu, Jingxia Liu, Meagan Jacoby, Samuel Urrutia, Nikolaos A. Trikalinos

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Batista, J., Iglesia, M., Kim, H., et al. (2026). Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center. Endocrine Oncology. https://doi.org/10.1530/eo-26-0038

Related articles

• [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial · The Lancet · 2026 · Cites or is cited by this article
• HbA1c screening in patients with early breast cancer receiving endocrine therapy · Endocrine Oncology · 2025 · Same journal
• Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas · Endocrine Oncology · 2025 · Same journal
• Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE · Endocrine Oncology · 2025 · Same journal
• 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence · Endocrine Oncology · 2025 · Same journal
• Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes · Endocrine Oncology · 2025 · Same journal
• To screen or not to screen: complexity of SDHA mutation management · Endocrine Oncology · 2026 · Same journal
• Adrenal crisis due to pembrolizumab-induced hypophysitis in a patient with triple-negative breast cancer · Endocrine Oncology · 2025 · Same journal
• Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer · Endocrine Oncology · 2025 · Same journal
• Patient-reported symptom and urgent healthcare use in neuroendocrine tumors · Endocrine Oncology · 2026 · Same journal